Skip to main content
Research

Publications: Ms Julia Gutjahr

Rot A, Gutjahr JC, Biswas A, Aslani M, Hub E, Thiriot A, von Andrian UH, Megens RTA et al. ( 2022 ) . Murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1 . Cell Stem Cell vol. 29 , ( 7 ) 1013 - 1015 .
Yu X, Munoz-Sagredo L, Streule K, Muschong P, Bayer E, Walter RJ, Gutjahr JC, Greil R et al. ( 2021 ) . CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues . Blood vol. 138 , ( 12 ) 1067 - 1080 .
Gutjahr JC, Crawford KS, Jensen DR, Naik P, Peterson FC, Samson GPB, Legler DF, Duchene J et al. ( 2021 ) . The dimeric form of CXCL12 binds to atypical chemokine receptor 1 . Science Signaling vol. 14 , ( 696 ) eabc9012 - eabc9012 .
Gutjahr JC, Bayer E, Yu X, Laufer JM, Höpner JP, Tesanovic S, Härzschel A, Auer G et al. ( 2021 ) . CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity . Haematologica vol. 106 , ( 8 ) 2102 - 2113 .
Werth K, Hub E, Gutjahr JC, Bosjnak B, Zheng X, Bubke A, Russo S, Rot A et al. ( 2021 ) . Expression of ACKR4 demarcates the “peri-marginal sinus,” a specialized vascular compartment of the splenic red pulp . Cell Reports vol. 36 , ( 2 )
Crawford K, Gutjahr J, Rot A, Volkman B ( 2021 ) . Dimeric CXCL12 (SDF‐1) binds to atypical chemokine receptor 1 (ACKR1/DARC) . The FASEB Journal . vol. 35 ,
Szenes E, Härzschel A, Decker S, Tissino E, Pischeli J, Gutjahr JC, Kissel S, Pennisi S et al. ( 2020 ) . TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia . Leukemia vol. 34 , ( 9 ) 2498 - 2502 .
Gutjahr JC, Szenes E, Tschech L, Asslaber D, Schlederer M, Roos S, Yu X, Girbl T et al. ( 2018 ) . Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia . Blood vol. 131 , ( 12 ) 1337 - 1349 .
Tissino E, Benedetti D, Herman SEM, ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Bo MD et al. ( 2018 ) . Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia . Journal of Experimental Medicine vol. 215 , ( 2 ) 681 - 697 .
Catakovic K, Gassner FJ, Ratswohl C, Zaborsky N, Rebhandl S, Schubert M, Steiner M, Gutjahr JC et al. ( 2018 ) . TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia . OncoImmunology vol. 7 , ( 1 )
Roos S, Schlederer M, Hartmann T, Gutjahr JC, Szenes E, Tschech L, Girbl T, Greil R et al. ( 2017 ) . CLL cells residing in spleen and bone marrow microenvironments differ in their CD44 variant usage for migration and proliferation . LEUKEMIA & LYMPHOMA . vol. 58 , 41 - 42 .
Tissino E, Benedetti D, Herman SE, ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M et al. ( 2017 ) . INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE . HAEMATOLOGICA . vol. 102 , 229 - 229 .
Ganghammer S, Gutjahr J, Hutterer E, Krenn PW, Pucher S, Zelle-Rieser C, Jöhrer K, Wijtmans M et al. ( 2016 ) . Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors . Haematologica vol. 101 , ( 3 ) e99 - e102 .
Gutjahr JC, Greil R, Hartmann TN ( 2015 ) . The role of CD44 in the pathophysiology of chronic lymphocytic leukemia . Frontiers in Immunology vol. 6 , ( MAR )